Intravenous benzodiazepines as anaesthetic agents: pharmacokinetics and clinical consequences.
Despite extensive and numerous pharmacokinetic studies on benzodiazepines, the published pharmacokinetic data do not adequately explain the clinical differences found between different benzodiazepine derivatives after intravenous administration. Especially, correlations between initial drug responses and distributional changes of the benzodiazepines are limited. However, during the elimination phase some relationships exist between the kinetic and dynamic phenomena. Age, sex, diseases and concomitantly given drugs cause clinically important alterations in the pharmacokinetics of benzodiazepines. Generally these anxiolytics and sedatives should be considered as adjuvants to general anaesthesia, but not primarily as routine induction agents. The major reasons for this limitation are a high variability in drug response, a relatively slow onset of action and long-lasting residual effects. However, benzodiazepines have many important advantages (see Table 5) when used as intravenous inducing agents of general anaesthesia.
D000328:Adult; D000368:Aged; D000766:Anesthesia, Dental; D000768:Anesthesia, General; D000771:Anesthesia, Intravenous; D000777:Anesthetics / Q000008:administration & dosage / Q000378:metabolism*; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000378:metabolism*; D001569:Benzodiazepines; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged
D000777:Anesthetics; D014151:Anti-Anxiety Agents; D001569:Benzodiazepines